These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3227516)

  • 41. [Drug-eruptions].
    Thielen AM; Toutous-Trellu L; Desmeules J
    Rev Med Suisse; 2008 Jul; 4(165):1671-5. PubMed ID: 18767294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 43. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 46. [Drug effects in elderly subjects: from the pharmacologic target to the risk-benefit. Round Table #5 of the 16th National Clinical Pharmacology Workshop].
    Lassale C; Piette F; Jolliet P
    Therapie; 2001; 56(4):363-7. PubMed ID: 11677853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 48. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 49. Post-marketing surveillance of drugs.
    Bell KD
    Med J Aust; 1991 Apr; 154(8):567. PubMed ID: 2064665
    [No Abstract]   [Full Text] [Related]  

  • 50. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The diagnosis of adverse medical events associated with drug treatment.
    Stephens MD
    Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
    [No Abstract]   [Full Text] [Related]  

  • 52. Multicenter study of hospital adverse drug reactions.
    Conforti A; Leone R; Moretti U; Sartori M; Velo GP
    Acta Physiol Hung; 1990; 75 Suppl():63-4. PubMed ID: 2196759
    [No Abstract]   [Full Text] [Related]  

  • 53. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 54. Assessing risk in postmarketing surveillance.
    Cerrito PB; Cerrito JC
    J Biopharm Stat; 1991; 1(2):221-35. PubMed ID: 1844698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonlinear neural mapping analysis of the adverse effects of drugs.
    Domine D; Guillon C; Devillers J; Lacroix R; Lacroix J; Doré JC
    SAR QSAR Environ Res; 1998; 8(1-2):109-20. PubMed ID: 9517012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 58. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 59. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

  • 60. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.